Slide 1

**Drug Formulary Commission**

Bureau of Health Care Safety and Quality

Department of Public Health

May 18, 2017

Slide 2

**Presentation Agenda**

* Interchangeable Abuse Deterrent Drug Products Evaluation
  + Morphabond ER®
  + Arymo ER®
* Chemically Equivalent Substitutions
  + Morphabond ER®
  + Arymo ER®
* Draft Formulary
  + 105 CMR 720: *List of Interchangeable Drug Products*
  + aka *Drug Formulary Commission*
* Next Steps

Slide 3

**Formulary Review and Evaluation**

* Component 1: Opioids with a Heightened Public Health Risk
* Component 2: Interchangeable Abuse Deterrent Opioids
* Component 3: “Cross Walk” – Chemically Equivalent Substitutions
* Draft Amended Formulary

Slide 4

**Potential IAD Drug Product Evaluation MorphaBond ER®**

**MorphaBond ER® Monograph Review**

* Morphine sulfate extended-release
* ADF Property
  + Physical/Chemical Barrier
  + *In vitro* studies indicate intravenous abuse deterrence
  + Clinical abuse potential study of the intranasal route
* FDA Approval October 2015
* FDA ADF labeling approved October 2015
* Available Strengths
  + 15 mg, 30 mg, 60 mg, 100 mg

Slide 5

**Potential IAD Drug Product Evaluation MorphaBond ER®**

* MorphaBond ER® is formulated as an extended-release tablet.1
* The abuse-deterrent technology platform is referred to as SentryBond®.3
* *In vitro* manipulation study data indicates that MorphaBond® is difficult to crush or cut using most household tools.2
* Attempts to dissolve MorphaBond ER® results in formation of a viscous material that is not syringeable.2
* Efforts to extract morphine from MorphaBond ER® tablets in small volumes generally results in low yields over 30 minutes.2
* Extraction of morphine from MorphaBond ER® in larger volumes is limited to 30 to 40% over 30 minutes in one household solvent.2
* An intranasal clinical abuse potential study indicates that crushed intranasal MorphaBond ER® is associated with less drug liking than crushed intranasal MS Contin®. 4

Slide 6

**Potential IAD Drug Product Evaluation MorphaBond ER®**

* Initial dose (opioid naïve adults): 15 mg every 12 hours.1
* Initial dose (converting from other opioids):15 mg every 12 hours.1
* Median time to peak plasma concentration (Tmax) of an intact MorphaBond ER® tablet taken orally is approximately 1.6 hours.2,9
* Median Tmax for crushed MorphaBond ER® tablets used intranasally is also approximately 1.6 hours; however, the plasma exposure (AUC) to morphine and morphine-6-glucuronide is approximately 37% lower than when taken intact orally.2,9
* *In vitro* data indicates MorphaBond ER® does not have a dose-dumping effect; therefore, the FDA did not require an *in vivo* alcohol dose-dumping study.9
* Administration of MorphaBond ER® with a high fat meal resulted in a 33% increase in peak plasma concentration (Cmax), but no change in AUC compared to fasted state.1

Slide 7  
**Potential IAD Drug Product Evaluation MorphaBond ER®**

* MorphaBond ER® is subject to the requirements of the Extended-Release and Long-Acting (ER/LA) Risk Evaluation and Mitigation Strategies (REMS) program.2
* There was no advisory committee meeting prior to approval of MorphaBond ER®.
* Final report submissions of formal observational studies, intended to determine if the abuse-deterrent properties of Troxyca ER® reduce abuse in the community, are due to the FDA in February of 2021.9

Slide 8

**Potential IAD Drug Product Evaluation MorphaBond ER®**

**MorphaBond ER® Summary**

* Chemical name morphine sulfate
* Dosage form Extended-release tablet
* Formulation SentryBond® tablet technology
* ADP\* Physical/Chemical Barrier
* ADF studies Intranasal and intravenous (*invitro*)
* ADF labeling Intranasal and Intravenous

\*ADP = Abuse-deterrent properties

Slide 9

**Potential IAD Drug Product Evaluation Arymo ER®**

**Arymo ER® Monograph Review**

* Morphine sulfate extended-release
* ADF Property
  + Physical/Chemical Barrier
  + *In vitro* studies indicate intravenous abuse deterrence
  + Clinical abuse potential studies of the intranasal and oral routes
* FDA Approval January 2017
* FDA ADF labeling approved January 2017
* Available Strengths
  + 15 mg, 30 mg, 60 mg

Slide 10

**Potential IAD Drug Product Evaluation Arymo ER®**

* Arymo ER® is formulated as an extended-release tablet.1
* The abuse-deterrent technology platform is referred to as Guardian®, which combines a polymer matrix with an injection molding process to make the tablet more difficult to manipulate.2
* *In vitro* manipulation study data indicates that Arymo ER® is difficult to crush or cut using household tools, and may require use of multiple tools to obtain 5% of morphine particles smaller than 500 microns.2
* Attempts to dissolve Arymo ER® results in formation of a viscous material that is only syringeable with an 18 gauge needle, and approximately 16 to 18% of the material can be drawn up.2
* Efforts to extract morphine from Arymo ER® tablets in large volumes of solvents is limited to less than 60% of morphine over 30 minutes.2
* A simulated smoking and free-base isolation study indicates that isolation of free-base morphine was not successful on three attempts, and less than 3% of morphine was released in vapor upon simulating smoking.

Slide 11

**Potential IAD Drug Product Evaluation Arymo ER®**

* An oral clinical abuse potential study revealed that manipulated Arymo ER® taken orally was associated with less drug liking than manipulated morphine ER tablets (generic MS Contin®).4
* An intranasal clinical abuse potential study revealed that both low volume and high volume manipulated Arymo ER® intranasal was associated with less drug liking than manipulated morphine ER tablets (generic MS Contin®).5

Slide 12

**Potential IAD Drug Product Evaluation Arymo ER®**

* Initial dose (opioid naïve adults): 15 mg every 8 or 12 hours.1
* Initial dose (converting from other opioids):15 mg every 8 or 12 hours.1
* Mean (standard deviation [SD]) time to peak plasma concentration (Tmax) of an intact Arymo ER® tablet taken orally in the oral clinical abuse potential study was 3.6 (1.1) hours.4
* Mean (SD) Tmax for manipulated Arymo ER® tablets taken orally in the oral clinical abuse potential study was 2.0 (0.7) hours; however, the mean (SD) plasma exposure (AUC) to morphine was slightly lower for the manipulated Arymo ER® compared to intact (159.3 [36.8] ng●hr/mL versus 168.0 [53.6] ng●hr/mL, respectively)4
* *In vitro* data indicates that as alcohol concentrations increase, the release rate of morphine from Arymo ER® is slower.2
* There is no clinically significant food effect on Arymo ER®; however, Tmax may be delayed by approximately 2 hours.1

Slide 13  
**Potential IAD Drug Product Evaluation Arymo ER®**

* Arymo ER® is subject to the requirements of the Extended-Release and Long-Acting (ER/LA) Risk Evaluation and Mitigation Strategies (REMS) program.2

|  |  |  |
| --- | --- | --- |
|  | **Oral ADF** | **Intranasal ADF** |
| FDA Advisory Committee6 | 16-3 vote in favor | 18-1 vote in favor |
| FDA Labeling7 | Yes | No |

* Final report submissions of formal observational studies, intended to determine if the abuse-deterrent properties of Arymo ER® reduce abuse in the community, are due to the FDA in March of 2022.13

Slide 14

**Future Review Process**

**Arymo ER® Summary**

* Chemical name morphine sulfate
* Dosage form Extended-release tablet
* Formulation Guardian® tablet technology
* ADP\* Physical/Chemical Barrier
* ADF studies Intranasal, oral and intravenous (*in vitro*)
* ADF labeling Oral and Intravenous

\*ADP = Abuse-deterrent properties

Slide 15

**Potential IAD Drug Products – Updates**

* Vantrela ER®(hydrocodone extended-release)
  + FDA approved, launch reportedly planned for 1st Quarter 2017
  + Formulary Dossier not yet available
  + Monograph to be completed when commercially available
* RoxyBond® (oxycodone immediate-release)
  + FDA approved; however, not commercially available
  + Formulary Dossier not yet available
  + Monograph to be completed when commercially available

Slide 16

**Potential IAD Drug Products – Updates (Pipeline)**

* Egalet-002 (oxycodone ER)
  + Currently in Phase III
  + Uses Guardian® technology, similar to Arymo ER®
* KP606/IR (oxycodone prodrug)
  + Manufacturer expects human proof-of-concept data this year
  + 505(b)(2) New Drug Application (NDA) submission planned this year
* NKTR-181
  + New chemical entity µ-agonist designed to have reduced level of euphoria
  + Phase III: Met primary endpoint of significantly lower average pain intensity scores compared to placebo
  + Oral clinical abuse potential study: Significantly lower mean drug liking and drug high scores compared to oxycodone
  + FDA granted Fast Track designation

Slide 17

**Medication with ADF Claims or FDA Approved ADF Labeling**

Table: List of Medications with Abuse-Deterrent Claims or FDA-Approved Labeling

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Product Name** | **Manufacturer** | **Ingredient(s)** | **Dose Form** | **Method of Abuse Deterrence** | **DFC Action** |
| MorphaBond® | Inspirion Delivery Sciences/ Daiichi Sankyo | Morphine ER | Tablet | Physical/chemical barrier | PENDING |
| Arymo ER® | Egalet | Morphine ER | Tablet | Physical/chemical barrier | PENDING |
| Vantrela ER® | Teva | Hydrocodone ER | Tablet | Physical/chemical barrier | Not yet commercially available.  Launch planned for 1st Quarter 2017 |
| RoxyBond® | Inspirion Delivery Sciences | Oxycodone IR | Tablet | Physical/chemical barrier | FDA Approved  Not yet commercially available |
| Egalet-002 | Egalet | Oxycodone ER | Tablet | Physical/chemical barrier | Currently in Phase III |
| KP201/IR | KemPharm, Inc. | Hydrocodone IR | Undisclosed | Prodrug | NDA submission planned 2018 with Priority Review designation |
| NKTR-181 | Nektar Therapeutics | New chemical entity | Undisclosed, possibly solution | New Molecular Entity | FDA granted Fast Track designation |

Slide 18

**“Cross Walk”**

* Component 1: Opioids with a Heightened Public Health Risk
* Component 2: Interchangeable Abuse Deterrent Opioids
* Component 3: “Cross Walk” – Chemically Equivalent Substitutions
* Draft Amended Formulary

Slide 19

Chemically Equivalent Substitution

“Chemically Equivalent Substitution”, for the purpose of creating a formulary of drugs with abuse deterrent properties that the commission has determined may be appropriately substituted for opioids that have been determined to have a heightened public health risk due to the drugs’ potential for abuse and misuse, shall mean drug products which contain the same active ingredients, and are equivalent in strength or concentration, dosage form, and route of administration, and produce a comparable biologic effect. Prodrugs or ingredients without analgesic effect that are used solely for abuse deterrent formulations need not be equivalent.

Slide 20

Drug Product Criteria

… In considering whether a drug is a **chemically equivalent substitution** the commission shall consider:

* the **accessibility** of the drug and its proposed substitute;
* whether the drug's substitute is **cost** prohibitive;
* the **effectiveness** of the substitution (FDA approved for pain); and
* whether, based upon the current patterns of abuse and misuse, the drug's substitute incorporates abuse deterrent technology that will be an **effective deterrent** to such abuse and misuse.

Slide 21

**Cost Impact Methods**

* Utilization data (units dispensed) was collected from the PMP for 2016 for all Schedule II and III opioids.
* Total milligrams dispensed was calculated for each drug product (multiply units dispensed by strength for each strength, add results for each strength per product).
* Total cost of each drug product was calculated for 2017 (multiply units dispensed by WAC per strength, add results for each strength per product).
* Approximate cost per milligram was calculated for each drug product, in aggregate (divide total cost by total milligrams dispensed for each product).
* Cost of substitution was calculated by subtracting approximate cost per milligram of HPHR Opioid (in aggregate) from approximate cost per milligram of the IAD Drug Product(in aggregate), then multiplying the difference by units dispensed of the HPHR drug product in 2016.

Slide 22

**Cost Impact Methods**

* Results were provided ranging from 50% to 75% to 100% substitution, and results were also expressed as a percentage increase or decrease in cost.
* Tables on the following slides show exact matches in terms of milligram strengths between HPHR Opioid morphine ER products and Morphabond ER® or Arymo ER®; however, many other combinations exist that contain equivalent amounts of morphine per day and are potentially substitutable.
* Cost Impact calculations are based upon milligrams dispensed in attempt to capture cost of substitution for each product that is inclusive of all potential substitutions containing the same amount of morphine per day.
* Approximate patient impact is extracted from 2016 PMP data.

Slide 23

**Single-Dose Pharmacokinetic Data**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Drug** | **Dose** | **Peak Concentration (Cmax, mean [CV%])** | **Time to Peak Concentration (tmax, mean [CV%])** | **Elimination Half-Life (t1/2, mean [CV%])** | **Area Under the Curve (AUC0-∞, mean [CV%])** |
| Avinza® (morphine ER 24 hour capsule) | 60 mg | 7.2 (45.80%) ng/mL | 11.1 (68.47%) hours | 21.8 (42.66%) hours | 261.9 (31.08%) ng • hr/mL |
| Kadian® (morphine ER 12 or 24 hour capsule) | 100 mg | 13.19 (45.70%) ng/mL | 10 (6.00 to 24.00) hours\* | 33.83 (34.60%) hours | 390.98 (25.8%) ng • hr/mL |
| MorphaBond ER® (morphine ER tablet) | 100 mg | 33.39 (23.32%) ng/mL | 3.76 (28.91%) | 10.32 (24.76%) hours | 395.06 (23.23%) ng • hr/mL |
| Morphine ER tablet | 100 mg | 39.3 (42%) ng/mL | 2.6 hours† | Not reported | 401.6 (31%) ng • hr/mL |

CV=coefficient of variation, ER=extended-release Yellow=List A

\*Values represent median (range) Green=List B

†CV not reported

NDA/ANDA Data Source:

Drugs@FDA [database on the Internet]. Rockville (MD): Food and Drug Administration (US), Center for Drug Evaluation and Research; 2016 [cited 2017 May 11]. Available from: <http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm>.

Slide 24

**MorphaBond ER®**

**MorphaBond ER® and Morphine Extended-Release 24 Hour Capsule**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Medication** | **Active Ingredient** | **Strengths** | **Dosage Form** | **Route of Administration** | **Dosing Schedule** | **Cost/unit\*** | **Units Dispensed 2016** | **Approximate Cost 2016** | **ADP Efficacy** |
| **MorphaBond ER®** | **morphine sulfate** | **15 mg** | **extended-release tablet** | **Oral** | **Q12H** | **$5.40** | **-** | **-** | **Category II** |
| **30 mg** | **$10.80** | **-** | **-** |
| **60 mg** | **$16.98** | **-** | **-** |
| **Morphine extended-release 24 hour** | **morphine sulfate** | **30 mg** | **extended-release capsule** | **Oral** | **Q24H** | **$4.58** | **6,509** | **$29,835.30** | **N/A** |
| **60 mg** | **$8.90** | **9,616** | **$85,592.02** |
| **90 mg** | **$13.38** | **3,696** | **$49,465.05** |
| **120 mg** | **$15.79** | **6,446** | **$101,788.79** |

\*Wholesale acquisition cost per Online Red Book as of 3/15/2016 Yellow=List A

ADP=abuse-deterrent property, Q12H=every 12 hours, Q24H=every 24 hours Green=List B

Cost of Substitution (100% Conversion): $380,429

Cost of Substitution (75% Conversion): $285,322

Cost of Substitution (50% Conversion): $190,214

Percent Change in Cost: +108.18%

Possible Patient Impact: Approximately 139 Patients

Slide 25

**MorphaBond ER®**

**MorphaBond ER® and Kadian®**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Medication** | **Active Ingredient** | **Strengths** | **Dosage Form** | **Route of Administration** | **Dosing Schedule** | **Cost/unit\*** | **Units Dispensed 2016** | **Approximate Cost 2016** | **ADP Efficacy** |
| **MorphaBond ER®** | **morphine sulfate** | **15 mg** | **extended-release tablet** | **Oral** | **Q12H** | **$5.40** | **-** | **-** | **Category II** |
| **30 mg** | **$10.80** | **-** | **-** |
| **60 mg** | **$16.98** | **-** | **-** |
| **100 mg** | **$28.30** | **-** | **-** |
| **Kadian®** | **morphine sulfate** | **30 mg** | **extended-release capsule** | **Oral** | **Q12H or Q24H** | **$10.63** | **2,378** | **$25,273.38** | **N/A** |
| **60 mg** | **$21.26** | **8,949** | **$190,222.93** |
| **100 mg** | **$34.93** | **6,384** | **$222,976.10** |
| **200 mg** | **$71.76** | **270** | **$19,375.88** |

\*Wholesale acquisition cost per Online Red Book as of 3/15/2016 Yellow=List A

ADP=abuse-deterrent property, Q12H=every 12 hours, Q24H=every 24 hours Green=List B

Cost of Substitution (100% Conversion): -$108,530 (Cost Avoidance)

Cost of Substitution (75% Conversion): -$81,397 (Cost Avoidance)

Cost of Substitution (50% Conversion): -$54,265 (Cost Avoidance)

Percent Change in Cost: -16.60% Decrease in Cost

Possible Patient Impact: Approximately 86 Patients

Slide 26

**MorphaBond ER®**

**MorphaBond ER® and Morphine Extended-Release 12 or 24 Hour Capsule**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Medication** | **Active Ingredient** | **Strengths** | **Dosage Form** | **Route of Administration** | **Dosing Schedule** | **Cost/unit\*** | **Units Dispensed 2016** | **Approximate Cost 2016** | **ADP Efficacy** |
| **MorphaBond ER®** | **morphine sulfate** | **15 mg** | **extended-release tablet** | **Oral** | **Q12H** | **$5.40** | **-** | **-** | **Category II** |
| **30 mg** | **$10.80** | **-** | **-** |
| **60 mg** | **$16.98** | **-** | **-** |
| **100 mg** | **$28.30** | **-** | **-** |
| **Morphine extended-release 12 or 24 hour** | **morphine sulfate** | **30 mg** | **extended-release capsule** | **Oral** | **Q12H or Q24H** | **$4.55** | **32,122** | **$146,142.25** | **N/A** |
| **60 mg** | **$9.10** | **19,277** | **$175,401.42** |
| **100 mg** | **$15.21** | **19,946** | **$303,296.88** |

\*Wholesale acquisition cost per Online Red Book as of 3/15/2016 Yellow=List A

ADP=abuse-deterrent property, Q12H=every 12 hours, Q24H=every 24 hours Green=List B

Cost of Substitution (100% Conversion): $911,402

Cost of Substitution (75% Conversion): $683,551

Cost of Substitution (50% Conversion): $455,700

Percent Change in Cost: 78.34% Increase in Cost

Possible Patient Impact: Approximately 750 Patients

Slide 27

**MorphaBond ER®**

**MorphaBond ER® and MS Contin®**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Medication** | **Active Ingredient** | **Strengths** | **Dosage Form** | **Route of Administration** | **Dosing Schedule** | **Cost/unit\*** | **Units Dispensed 2016** | **Approximate Cost 2016** | **ADP Efficacy** |
| MorphaBond ER® | morphine sulfate | 15 mg | extended-release capsule | Oral | Q12H | $5.40 | - | - | Category II |
| 30 mg | $10.80 | - | - |
| 60 mg | $16.98 | - | - |
| 100 mg | $28.30 | - | - |
| MS Contin® | morphine sulfate | 15 mg | extended-release tablet | Oral | Q12H or Q8H | $3.61 | 10,055 | $36,302.57 | N/A |
| 30 mg | $6.86 | 8,590 | $58,931.70 |
| 60 mg | $13.39 | 19,964 | $267,258.07 |
| 100 mg | $19.82 | 10,316 | $204,465.18 |

\*Wholesale acquisition cost per Online Red Book as of 3/15/2016 Yellow=List A

ADP=abuse-deterrent property, Q8H=every 8 hours, Q12H=every 12 hours, Q24H=every 24 hours

Green=List B

Cost of Substitution (100% Conversion): $911,402

Cost of Substitution (75% Conversion): $683,551

Cost of Substitution (50% Conversion): $455,700

Percent Change in Cost: 78.34% Increase in Cost

Possible Patient Impact: Approximately 750 Patients

Slide 28

**MorphaBond ER®**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Medication** | **Active Ingredient** | **Strengths** | **Dosage Form** | **Route of Administration** | **Dosing Schedule** | **Cost/unit\*** | **Units Dispensed 2016** | **Approximate Cost 2016** | **ADP Efficacy** |
| MorphaBond ER® | morphine sulfate | 15 mg | extended-release capsule | Oral | Q12H | $5.40 | - | - | Category II |
| 30 mg | $10.80 | - | - |
| 60 mg | $16.98 | - | - |
| 100 mg | $28.30 | - | - |
| Morphine ER tablets | morphine sulfate | 15 mg | extended-release tablet | Oral | Q12H or Q8H | $0.60 | 3,418,799 | $2,056,407.60 | N/A |
| 30 mg | $1.14 | 2,839,373 | $3,245,971.21 |
| 60 mg | $2.23 | 1,336,022 | $2,980,130.67 |
| 100 mg | $3.30 | 470,586 | $1,551,192.63 |
| 200 mg | $5.99 | 44,189 | $264,904.22 |

\*Wholesale acquisition cost per Online Red Book as of 3/15/2016 Yellow=List A

ADP=abuse-deterrent property, Q8H=every 8 hours, Q12H=every 12 hours, Q24H=every 24 hours

Green=List B

Cost of Substitution (100% Conversion): $71,631,075

Cost of Substitution (75% Conversion): $53,723,306

Cost of Substitution (50% Conversion): $35,815,537

Percent Change in Cost: 709.32% Increase in Cost

Possible Patient Impact: Approximately 33,515 Patients

Slide 29

**MorphaBond ER®  - All Substitutions**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Medication** | **Active Ingredient** | **Strengths** | **Dosage Form** | **Route of Administration** | **Dosing Schedule** | **Cost/unit\*** | **Units Dispensed 2016** | **Approximate Cost 2016** | **ADP Efficacy** |
| **MorphaBond ER®** | **morphine sulfate** | **15 mg** | **extended-release capsule** | **Oral** | **Q12H** | **$5.40** | **-** | **-** | **Category II** |
| **30 mg** |
| **$10.80** | **-** | **-** |
| **60 mg** | **$16.98** | **-** | **-** |
| **100 mg** | **$28.30** | **-** | **-** |
| **Morphine extended-release 24 hour** | **morphine sulfate** | **30 mg** | **extended-release capsule** | **Oral** | **Q24H** | **$4.58** | **6,509** | **$29,835.30** | **N/A** |
| **60 mg** | **$8.90** | **9,616** | **$85,592.02** |
| **90 mg** | **$13.38** | **3,696** | **$49,465.05** |
| **120 mg** | **$15.79** | **6,446** | **$101,788.79** |
| **Kadian®** | **morphine sulfate** | **30 mg** | **extended-release capsule** | **Oral** | **Q12H or Q24H** | **$10.63** | **2,378** | **$25,273.38** | **N/A** |
| **60 mg** |
| **$21.26** | **8,949** | **$190,222.93** |
| **100 mg** | **$34.93** | **6,384** | **$222,976.10** |
| **200 mg** | **$71.76** | **270** | **$19,375.88** |
| **Morphine extended-release 12 or 24 hour** | **morphine sulfate** | **30 mg** | **extended-release capsule** | **Oral** | **Q12H or Q24H** | **$4.55** | **32,122** | **$146,142.25** | **N/A** |
| **60 mg** |
| **$9.10** | **19,277** | **$175,401.42** |
| **100 mg** | **$15.21** | **19,946** | **$303,296.88** |
| **MS Contin®** | **morphine sulfate** | **15 mg** | **extended-release tablet** | **Oral** | **Q12H or Q8H** | **$3.61** | **10,055** | **$36,302.57** | **N/A** |
| **30 mg** |
| **$6.86** | **8,590** | **$58,931.70** |
| **60 mg** | **$13.39** | **19,964** | **$267,258.07** |
| **100 mg** | **$19.82** | **10,316** | **$204,465.18** |
| **Morphine ER tablets** | **morphine sulfate** | **15 mg** | **extended-release tablet** | **Oral** | **Q12H or Q8H** | **$0.60** | **3,418,799** | **$2,056,407.60** | **N/A** |
| **30 mg** |
| **$1.14** | **2,839,373** | **$3,245,971.21** |
| **60 mg** | **$2.23** | **1,336,022** | **$2,980,130.67** |
| **100 mg** | **$3.30** | **470,586** | **$1,551,192.63** |
| **200 mg** | **$5.99** | **44,189** | **$264,904.22** |

Slide 30

**MorphaBond ER®**

**MorphaBond ER® and All List A Morphine Extended-Release Products - Continued**

Overall Cost of Substitution (100% Conversion): $73,038,550

Overall Cost of Substitution (75% Conversion): $54,778,913

Overall Cost of Substitution (50% Conversion): $36,519,275

Overall Percent Change: 569.08% Increase in Cost

Overall Possible Patient Impact: Approximately 34,574 Patients

Slide 31

**Arymo ER®**

**Arymo ER® and Morphine Extended-Release 24 Hour Capsule**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Medication** | **Active Ingredient** | **Strengths** | **Dosage Form** | **Route of Administration** | **Dosing Schedule** | **Cost/unit\*** | **Units Dispensed 2016** | **Approximate Cost 2016** | **ADP Efficacy** |
| **Arymo ER®** | **morphine sulfate** | **15 mg** | **extended-release tablet** | **Oral** | **Q12H or Q8H** | **$5.40** | **-** | **-** | **Category II** |
| **30 mg** | **$10.80** | **-** | **-** |
| **60 mg** | **$16.98** | **-** | **-** |
| **Morphine extended-release 24 hour** | **morphine sulfate** | **30 mg** | **extended-release capsule** | **Oral** | **Q24H** | **$4.58** | **6,509** | **$29,835.30** | **N/A** |
| **45 mg** | **$6.80** | **6,482** | **$44,054.26** |
| **60 mg** |
| **$8.90** | **9,616** | **$85,592.02** |
| **90 mg** | **$13.38** | **3,696** | **$49,465.05** |
| **120 mg** | **$15.79** | **6,446** | **$101,788.79** |

\*Wholesale acquisition cost per Online Red Book as of 3/15/2016 Yellow=List A

ADP=abuse-deterrent property, Q12H=every 12 hours, Q24H=every 24 hours Green=List B

Cost of Substitution (100% Conversion): $352,071

Cost of Substitution (75% Conversion): $264,053

Cost of Substitution (50% Conversion): $176,035

Percent Change in Cost: +100.11%

Possible Patient Impact: Approximately 139 Patients

Slide 32

**Arymo ER®**

**Arymo ER® and Kadian®**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Medication** | **Active Ingredient** | **Strengths** | **Dosage Form** | **Route of Administration** | **Dosing Schedule** | **Cost/unit\*** | **Units Dispensed 2016** | **Approximate Cost 2016** | **ADP Efficacy** |
| Arymo ER® | morphine sulfate | 15 mg | extended-release tablet | Oral | Q12H or Q8H | $5.40 | - | - | **Category II** |
| 30 mg | $10.80 | - | - |
| 60 mg | $16.98 | - | - |
| Kadian® | morphine sulfate | 30 mg | extended-release capsule | Oral | Q12H or Q24H | $10.63 | 2,378 | $25,273.38 | **N/A** |
| 60 mg | $21.26 | 8,949 | $190,222.93 |

\*Wholesale acquisition cost per Online Red Book as of 3/15/2016 Yellow=List A

ADP=abuse-deterrent property, Q12H=every 12 hours, Q24H=every 24 hours Green=List B

Cost of Substitution (100% Conversion): -$129,653 (Cost Avoidance)

Cost of Substitution (75% Conversion): -$97,240 (Cost Avoidance)

Cost of Substitution (50% Conversion): -$64,827 (Cost Avoidance)

Percent Change in Cost: -19.83% Decrease in Cost

Possible Patient Impact: Approximately 86 Patients

Slide 33

**Arymo ER®**

**Arymo ER® and Morphine Extended-Release 12 or 24 Hour Capsule**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Medication** | **Active Ingredient** | **Strengths** | **Dosage Form** | **Route of Administration** | **Dosing Schedule** | **Cost/unit\*** | **Units Dispensed 2016** | **Approximate Cost 2016** | **ADP Efficacy** |
| **Arymo ER®** | **morphine sulfate** | **15 mg** | **extended-release tablet** | **Oral** | **Q12H or Q8H** | **$5.40** | **-** | **-** | **Category II** |
| **30 mg** | **$10.80** | **-** | **-** |
| **60 mg** | **$16.98** | **-** | **-** |
| **Morphine extended-release 12 or 24 hour** | **morphine sulfate** | **30 mg** | **extended-release capsule** | **Oral** | **Q12H or Q24H** | **$4.55** | **32,122** | **$146,142.25** | **N/A** |
| **60 mg** | **$9.10** | **19,277** | **$175,401.42** |

\*Wholesale acquisition cost per Online Red Book as of 3/15/2016 Yellow=List A

ADP=abuse-deterrent property, Q12H=every 12 hours, Q24H=every 24 hours Green=List B

Cost of Substitution (100% Conversion): $831,034

Cost of Substitution (75% Conversion): $623,276

Cost of Substitution (50% Conversion): $415,517

Percent Change in Cost: 71.43% Increase in Cost

Possible Patient Impact: Approximately 750 Patients

Slide 34

**Arymo ER®**

**Arymo ER® and MS Contin®**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Medication** | **Active Ingredient** | **Strengths** | **Dosage Form** | **Route of Administration** | **Dosing Schedule** | **Cost/unit\*** | **Units Dispensed 2016** | **Approximate Cost 2016** | **ADP Efficacy** |
| MorphaBond ER® | morphine sulfate | 15 mg | extended-release capsule | Oral | Q12H | $5.40 | - | - | Category II |
| 30 mg | $10.80 | - | - |
| 60 mg | $16.98 | - | - |
| MS Contin® | morphine sulfate | 15 mg | extended-release tablet | Oral | Q12H or Q8H | $3.61 | 10,055 | $36,302.57 | N/A |
| 30 mg | $6.86 | 8,590 | $58,931.70 |
| 60 mg | $13.39 | 19,964 | $267,258.07 |

\*Wholesale acquisition cost per Online Red Book as of 3/15/2016 Yellow=List A

ADP=abuse-deterrent property, Q8H=every 8 hours, Q12H=every 12 hours, Q24H=every 24 hours Green=List B

Cost of Substitution (100% Conversion): $139,530

Cost of Substitution (75% Conversion): $145,148

Cost of Substitution (50% Conversion): $96,765

Percent Change in Cost: 34.13% Increase in Cost

Possible Patient Impact: Approximately 84 Patients

Slide 35

**Arymo ER®**

**Arymo ER® and Morphine Extended-Release Tablet**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Medication** | **Active Ingredient** | **Strengths** | **Dosage Form** | **Route of Administration** | **Dosing Schedule** | **Cost/unit\*** | **Units Dispensed 2016** | **Approximate Cost 2016** | **ADP Efficacy** |
| **MorphaBond ER®** | **morphine sulfate** | **15 mg** | **extended-release capsule** | **Oral** | **Q12H** | **$5.40** | **-** | **-** | **Category II** |
| **30 mg** | **$10.80** | **-** | **-** |
| **60 mg** | **$16.98** | **-** | **-** |
| **Morphine ER tablets** | **morphine sulfate** | **15 mg** | **extended-release tablet** | **Oral** | **Q12H or Q8H** | **$0.60** | **3,418,799** | **$2,056,407.60** | **N/A** |
| **30 mg** | **$1.14** | **2,839,373** | **$3,245,971.21** |
| **60 mg** | **$2.23** | **1,336,022** | **$2,980,130.67** |

\*Wholesale acquisition cost per Online Red Book as of 3/15/2016 Yellow=List A

ADP=abuse-deterrent property, Q8H=every 8 hours, Q12H=every 12 hours, Q24H=every 24 hours Green=List B

Cost of Substitution (100% Conversion): $68,465,275

Cost of Substitution (75% Conversion): $51,348,956

Cost of Substitution (50% Conversion): $34,232,637

Percent Change in Cost: 677.97% Increase in Cost

Possible Patient Impact: Approximately 33,515 Patients

Slide 36

**Arymo ER®**

**Arymo ER® and All List A Morphine Extended-Release Products**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Medication** | **Active Ingredient** | **Strengths** | **Dosage Form** | **Route of Administration** | **Dosing Schedule** | **Cost/unit\*** | **Units Dispensed 2016** | **Approximate Cost 2016** | **ADP Efficacy** |
| **Arymo ER®** | **morphine sulfate** | **15 mg** | **extended-release capsule** | **Oral** | **Q12H** | **$5.40** | **-** | **-** | **Category II** |
| **30 mg** |
| **$10.80** | **-** | **-** |
| **60 mg** | **$16.98** | **-** | **-** |
| **Morphine extended-release 24 hour** | **morphine sulfate** | **30 mg** | **extended-release capsule** | **Oral** | **Q24H** | **$4.58** | **6,509** | **$29,835.30** | **N/A** |
| **45 mg** |  |  |  |
| **60 mg** | **$8.90** | **9,616** | **$85,592.02** |
| **90 mg** | **$13.38** | **3,696** | **$49,465.05** |
| **120 mg** | **$15.79** | **6,446** | **$101,788.79** |
| **Kadian®** | **morphine sulfate** | **30 mg** | **extended-release capsule** | **Oral** | **Q12H or Q24H** | **$10.63** | **2,378** | **$25,273.38** | **N/A** |
| **60 mg** | **$21.26** | **8,949** | **$190,222.93** |
| **Morphine extended-release 12 or 24 hour** | **morphine sulfate** | **30 mg** | **extended-release capsule** | **Oral** | **Q12H or Q24H** | **$4.55** | **32,122** | **$146,142.25** | **N/A** |
| **60 mg** | **$9.10** | **19,277** | **$175,401.42** |
| **MS Contin®** | **morphine sulfate** | **15 mg** | **extended-release tablet** | **Oral** | **Q12H or Q8H** | **$3.61** | **10,055** | **$36,302.57** | **N/A** |
| **30 mg** |
| **$6.86** | **8,590** | **$58,931.70** |
| **60 mg** | **$13.39** | **19,964** | **$267,258.07** |
| **Morphine ER tablets** | **morphine sulfate** | **15 mg** | **extended-release tablet** | **Oral** | **Q12H or Q8H** | **$0.60** | **3,418,799** | **$2,056,407.60** | **N/A** |
| **30 mg** |
| **$1.14** | **2,839,373** | **$3,245,971.21** |
| **60 mg** | **$2.23** | **1,336,022** | **$2,980,130.67** |

Slide 37

**Arymo ER®**

**Arymo ER® and All List A Morphine Extended-Release Products - Continued**

Overall Cost of Substitution (100% Conversion): $69,712,256

Overall Cost of Substitution (75% Conversion): $52,284,192

Overall Cost of Substitution (50% Conversion): $34,856,128

Overall Percent Change: 543.16% Increase in Cost

Overall Possible Patient Impact: Approximately 34,574 Patients

Slide 38

**Promulgation of Regulation and Formulary**

History

* Proposed 105 CMR 720, *List of Interchangeable Drug Products,* including draft formulary, as redrafted, to the Public Health Council (11/9/2016)
* Public hearing held on proposed changes to regulation (1/19/2017)

Current

* DPH staff is reviewing comments and further amending as appropriate.

Pending

* DPH staff will present the final draft regulation to PHC for promulgation.
* Review by Secretary of State 🡪 Regulation becomes effective.

Next Step

* Issue guidance, including special substitution considerations, and the requirements and process of substitution.
* Conduct prescriber education on abuse deterrent substitutes.

Slide 39

**Meeting Summary**

* Meeting Recap
* Review of takeaways
* Next steps
* Upcoming Meetings
  + June 20, 2017
    - 9:00AM-12:00PM
    - 250 Washington Street